Bruno Sepodes

PhD (2008) in Pharmacy (Pharmacology), Universidade de Lisboa
Assistant professor, Pharmacological Sciences , Faculdade de Farmácia, Universidade de Lisboa

Faculdade de Farmácia, Universidade de Lisboa — Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal

T (+351) 217 946 400
F (+351) 217 946 470
Researcher ID A-4838-2014
Group Researcher ID B-5723-2014
Scopus Author ID 6507271629

Research Interests

Bruno’s basic research focuses on the identification of new pharmacological targets in the area of local and systemic inflammation and in the translation to the clinical setting. He is also active in Regulatory Sciences and Public Health, namely in the field of rare diseases. Bruno is currently the Chair of the Committee of Orphan Medicinal Products and member of the Scientific Coordination Board, member of the Committee of Human Medicinal Products (CHMP) and of the Committee of Advanced Therapies (CAT) of the European Medicines Agency.

Selected Publications

Aartsma-Rus A, Straub V, Hemmings R, Haas M, Schlosser-Weber G, Stoyanova-Beninska V, Mercuri E, Muntoni F, Sepodes B, Vroom E, Balabanov P. Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues. Nucleic Acid Ther 2017; 27: 251-259.

Straub V, Balabanov P, Bushby K, Ensini M, Goemans N, De Luca A, Pereda A, Hemmings R, Campion G, Kaye E, Arechavala-Gomeza V, Goyenvalle A, Niks E, Veldhuizen O, Furlong P, Stoyanova-Beninska V, Wood MJ, Johnson A, Mercuri E, Muntoni F, Sepodes B, Haas M, Vroom E, Aartsma-Rus A. Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. Lancet Neurol 2016; 15: 882-90.

Mariz S, Reese JH, Westermark K, Greene L, Goto T, Hoshino T, Llinares-Garcia J, Sepodes B. Worldwide collaboration for orphan drug designation. Nat Rev Drug Discov 2016; 15: 440-41.

Vaquer G, Rivière F, Mavris M, Bignami F, Llinares-Garcia J, Westermark K, Sepodes B. Animal models for metabolic, neuromuscular and ophthalmological rare diseases. Nat Rev Drug Discov 2013; 12: 287-305.

Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A 2008; 105: 10925-30.